4.7 Review

Non-Peptidic Small Molecule Inhibitors Against Bcl-2 for Cancer Therapy

Journal

JOURNAL OF CELLULAR PHYSIOLOGY
Volume 218, Issue 1, Pages 13-21

Publisher

WILEY
DOI: 10.1002/jcp.21567

Keywords

-

Funding

  1. National Institute of Health [R01 CAI 09389]
  2. Leukemia Lymphoma CA [109389]
  3. Leukemia and Lymphoma Society [6028-07]

Ask authors/readers for more resources

A critical regulator of the apoptotic machinery is the Bcl-2 family proteins whose over expression confers a protective effect on malignant cells against death signals of apoptosis. Cancer cells that are resistant to various anti-cancer drugs and treatment regimen are found to over express these Bcl-2 proteins such as Bcl-2, Bcl-X-L, Mcl-1, Bcl-w, and AI/Bfl1. In recent years there has been an exponential growth in the identification as well as synthesis of non-peptidic cell permeable small-molecule inhibitors (SMIs) of protein-protein interaction. The focus of this article is on inhibitors of anti-apoptotic protein Bcl-2. This review summarizes an up to date knowledge of the available SMIs their mode of action as well as their current status in preclinical as well as clinical development.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available